Press Releases

Binding Cell Receptors Key to New Prostate Cancer Diagnostic Test from NuView Life Sciences

By March 13, 2019April 5th, 2019No Comments

A recent study validating urine diagnosis for cancer cell receptors in prostate cancer is eclipsing traditional methodology and warrants further steps toward FDA approval says cutting-edge biotechnology leader, NuView Life Sciences. CEO Paul Crowe will present the findings to the Boston Oncology Investor Conference, outlining the steps in the successful study and addressing the technology’s future.  …more…